Filing Details
- Accession Number:
- 0000950170-23-070841
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-12-15 17:38:20
- Reporting Period:
- 2023-12-13
- Accepted Time:
- 2023-12-15 17:38:20
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1582313 | Xenon Pharmaceuticals Inc. | XENE | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1283535 | Gary Patou | 200 - 3650 Gilmore Way Burnaby A1 V5G 4W8 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Shares | Acquisiton | 2023-12-13 | 6,378 | $9.85 | 29,951 | No | 4 | M | Direct | |
| Common Shares | Disposition | 2023-12-13 | 1,278 | $39.68 | 28,673 | No | 4 | F | Direct | |
| Common Shares | Disposition | 2023-12-13 | 5,100 | $38.94 | 23,573 | No | 4 | S | Direct | |
| Common Shares | Acquisiton | 2023-12-13 | 2,880 | $9.85 | 26,453 | No | 4 | M | Direct | |
| Common Shares | Disposition | 2023-12-13 | 577 | $39.68 | 25,876 | No | 4 | F | Direct | |
| Common Shares | Disposition | 2023-12-13 | 2,303 | $39.10 | 23,573 | No | 4 | S | Direct | |
| Common Shares | Acquisiton | 2023-12-13 | 5,144 | $9.00 | 28,717 | No | 4 | M | Direct | |
| Common Shares | Disposition | 2023-12-13 | 1,167 | $39.68 | 27,550 | No | 4 | F | Direct | |
| Common Shares | Disposition | 2023-12-13 | 3,977 | $39.84 | 23,573 | No | 4 | S | Direct | |
| Common Shares | Disposition | 2023-12-13 | 7,598 | $41.05 | 4,902 | No | 4 | S | Indirect | See Note |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Indirect | See Note |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Shares | Stock Option (Right to Buy) | Disposition | 2023-12-13 | 6,378 | $0.00 | 6,378 | $9.85 |
| Common Shares | Stock Option (Right to Buy) | Disposition | 2023-12-13 | 2,800 | $0.00 | 2,800 | $9.85 |
| Common Shares | Stock Option (Right to Buy) | Disposition | 2023-12-13 | 5,144 | $0.00 | 5,144 | $9.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2016-12-31 | 2024-01-13 | No | 4 | M | Direct |
| 0 | 2016-12-31 | 2024-01-13 | No | 4 | M | Direct |
| 0 | 2017-11-04 | 2024-11-03 | No | 4 | M | Direct |
Footnotes
- Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period.
- The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
- Represents the closing price of the Company's common shares in U.S. dollars on December 12, 2023, which was converted to a Canadian dollar amount for purposes of net settlement calculations.
- The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.81 to $39.13, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $39.04 to $39.16, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.06, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou.
Billionaire Hedge Funds
